A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes
Skp. Kung et al., A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes, J VIROLOGY, 74(8), 2000, pp. 3668-3681
We constructed human immunodeficiency virus type 1 (HIV-1) vectors that wil
l allow higher levels of gene expression in T cells. Gene expression under
the control of an internal cytomegalovirus (CMV) immediate-early promoter i
n a self-inactivating lentiviral vector (CSCG) is 4- to 15-fold lower in T-
cell lines (SUPT1 and CEMX174) than in non-lymphoid-cell lines (HeLa and 29
3T), This is in contrast to a Moloney murine leukemia virus (MoMLV)-based r
etrovirus vector (SR alpha LEGFP), We therefore replaced the internal CMV p
romoter of CSCG with three different murine oncoretroviral long terminal re
peat (LTR) promoters - murine sarcoma virus (MSV), MoMLV (MLV), and the LTR
(termed Rh-MLV) that is derived from the ampho-mink cell focus-forming (AM
P/MCF) retrovirus in the serum of one rhesus macaque monkey that developed
T cell lymphoma following autologous transplantation of enriched bone marro
w stem cells transduced with a retrovirus vector preparation containing rep
lication-competent viruses (E. F, Vanin, M, Kaloss, C, Broscius, and A. W,
Nienhuis, J, Virol, 68:4241-4250, 1994), We found that the combination of R
h-MLV LTR and a partial gag sequence of MoMLV (Delta gag(871-1612)) in CS-R
h-MLV-E gave the highest level of enhanced green fluorescent protein (EGFP)
gene expression compared with MLV, MSV LTR, phosphoglycerate kinase, and C
MV promoters in T-cell lines, as well as activated primary T cells. Interes
tingly, there was a further two- to threefold increase in EGFP expression (
thus, 10 fold-higher expression than with CMV) when the Rh-MLV promoter and
Delta gag(871-1612) were used in a self-inactivating-vector setting that h
as a further deletion in the U3 region of the HIV-1 LTR, These hybrid vecto
rs should prove useful in gene therapy applications for T cells.